Mon, 14th Jul 2008 08:17 LONDON (Thomson Financial) - Physiomics Plc. said it has agreed to perform two new cancer drug
discovery research projects for Eli Lilly.
The Oxford-based systems biology company said the agreement follows the completion of another cancer drug discovery project for Eli Lilly earlier this year for drug candidates targeting the cell cycle.
tf.TFN-Europe_newsdesk@thomson.com
jrr
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.